CA
SLS icon

Calton & Associates’s SELLAS Life Sciences SLS Stock Holding History

Calton & Associates’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Hold
11,000
– – 0.02% 413
2026
Q1 		$46.5K Hold
11,000
– – 0.01% 432
2025
Q4 		$41.5K Hold
11,000
– – 0.01% 442
2025
Q3 		$17.7K Hold
11,000
– – ﹤0.01% 424
2025
Q2 		$24.1K Hold
11,000
– – ﹤0.01% 382
2025
Q1 		$11.9K Buy
+11,000
New +$13.1K ﹤0.01% 338
2024
Q4 		– Sell
-14,000
Closed -$17.5K – 271
2024
Q3 		$17.5K Buy
+14,000
New +$17.1K 0.01% 240

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Calton & Associates's SLS Position: Q2 2026 in Review

Calton & Associates held its SELLAS Life Sciences (SLS) position steady in Q2 2026 at 11,000 shares worth $162K. The position accounts for 0.02% of the portfolio, ranked #413.

Calton & Associates first reported a position in SLS in Q3 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Calton & Associates held 11,000 shares of SELLAS Life Sciences worth $162K as of Q2 2026.
  • Calton & Associates left its SELLAS Life Sciences share count unchanged in Q2 2026.
  • SELLAS Life Sciences made up 0.02% of Calton & Associates's portfolio in Q2 2026, its #413 holding.
  • Calton & Associates first reported a position in SELLAS Life Sciences in Q3 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Calton & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.